Cargando…

Pulsed field versus cryoballoon ablation of atrial fibrillation: A comparison of efficacy and safety in a 400 patient cohort

FUNDING ACKNOWLEDGEMENTS: Type of funding sources: Private company. Main funding source(s): Boris Schmidt, KR Julian Chun and Stefano Bordignon received speaking honoraria from Medtronic and Boston Scientific BACKGROUND: The cryoballoon (CB) is one of the most commonly used single shot devices for p...

Descripción completa

Detalles Bibliográficos
Autores principales: Urbanek, L, Bordignon, S, Schaack, D, Chen, S, Plank, K, Hirokami, J, Schulte-Hahn, B, Schmidt, B, Chun, K R J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207474/
http://dx.doi.org/10.1093/europace/euad122.691
_version_ 1785046463010570240
author Urbanek, L
Bordignon, S
Schaack, D
Chen, S
Plank, K
Hirokami, J
Schulte-Hahn, B
Schmidt, B
Chun, K R J
author_facet Urbanek, L
Bordignon, S
Schaack, D
Chen, S
Plank, K
Hirokami, J
Schulte-Hahn, B
Schmidt, B
Chun, K R J
author_sort Urbanek, L
collection PubMed
description FUNDING ACKNOWLEDGEMENTS: Type of funding sources: Private company. Main funding source(s): Boris Schmidt, KR Julian Chun and Stefano Bordignon received speaking honoraria from Medtronic and Boston Scientific BACKGROUND: The cryoballoon (CB) is one of the most commonly used single shot devices for pulmonary vein isolation in patients with atrial fibrillation (AF). Pulsed field ablation (PFA) is a new non-thermal, tissue selective approach for pulmonary vein isolation. PURPOSE: We sought to compare procedural safety and efficacy of these single shot ablation techniques. METHODS: Consecutive AF patients (paroxysmal / persistent AF) who underwent CB based pulmonary vein isolation (PVI) between November 2020 and February 2022 were enrolled and compared with patients who underwent PFA ablation in the same time period. Patients that underwent ablation beyond PVI (except for cavo-tricuspid isthmus ablation) were excluded. CB PVI was performed using the second-generation CB (CB 28 mm) with 240 sec based freeze protocol and bonus freeze delivery in case of time-to-isolation (TTI) >75 sec. PFA was performed using the Farawave catheter, using the 31 or 35 mm device. All procedures were performed under deep sedation. RESULTS: Data from 400 consecutive patients were collected. Most baseline characteristics like age (CB: 67,5 ± 15,3; PFA: 68,4 ± 11; p=0,49), BMI (CB: 28,6 ± 6,3; PFA: 27,9 ± 5,6; p=0,27) and gender (male) (CB: 54%; PFA: 59%; p=0,31) were comparable between the two groups. All PVIs were successfully completed. In 98% (196) of patients in the CB group and 100% (200) in the PFA group, PVI was performed using solely CB or PFA respectively, meaning additional touch up ablation was only needed in 4 CB patients (2%; p=0,044) and 4 veins. Procedure time was significantly shorter in the PFA group (CB: 53 ± 15,3 minutes; PFA: 36,8 ± 13,5 minutes; p<0,001), whereas no difference in fluoroscopy time (CB: 8,1 ± 4,4 minutes; PFA: 7,8 ± 3,3 minutes; p=0,2) was observed. The rate of concomitant CTI-ablation was equal in both groups (CB: 1,5%; PFA: 1,5%; p=1,0). Complication rate was 3,5% with PFA and 6,5% in CB (p=0,17), a difference mostly driven by persistent phrenic nerve palsies (CB: 1,5%; PFA: 0%; p=0,08). All patients are out of the blanking period. There were 80 recurrences in blanking time (CB: 41; PFA: 39; p=0,8). In CB 19,5% of blanking time recurrences were atrial tachycardias compared to 35,9% in PFA (p=0,1). The average time to blanking recurrence was 14,1 ± 21,5 days in CB and 20,5 ± 23,2 in PFA (p=0,2). In total, there were 7 repeat procedures (4 in CB and 3 in PFA; p=0,7) during blanking time due to arrhythmias, despite of antiarrhythmic drugs and/or cardioversion. At the time of this analysis, the first hundred patients in each group reached one-year follow-up. Recurrence free survival after one year for patients with PAF was 82,6% in CB and 80,0% in PFA. In patients with persistent AF it was 70,8% in CB and 67,8% in PFA. CONCLUSION: Cryoballoon and pulsed field ablation are both highly effective and safe techniques for PVI. PFA had a shorter procedure time, whereas the one year follow up was similar for both techniques. [Figure: see text] [Figure: see text]
format Online
Article
Text
id pubmed-10207474
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-102074742023-05-25 Pulsed field versus cryoballoon ablation of atrial fibrillation: A comparison of efficacy and safety in a 400 patient cohort Urbanek, L Bordignon, S Schaack, D Chen, S Plank, K Hirokami, J Schulte-Hahn, B Schmidt, B Chun, K R J Europace 9.4.4 - Catheter Ablation of Arrhythmias FUNDING ACKNOWLEDGEMENTS: Type of funding sources: Private company. Main funding source(s): Boris Schmidt, KR Julian Chun and Stefano Bordignon received speaking honoraria from Medtronic and Boston Scientific BACKGROUND: The cryoballoon (CB) is one of the most commonly used single shot devices for pulmonary vein isolation in patients with atrial fibrillation (AF). Pulsed field ablation (PFA) is a new non-thermal, tissue selective approach for pulmonary vein isolation. PURPOSE: We sought to compare procedural safety and efficacy of these single shot ablation techniques. METHODS: Consecutive AF patients (paroxysmal / persistent AF) who underwent CB based pulmonary vein isolation (PVI) between November 2020 and February 2022 were enrolled and compared with patients who underwent PFA ablation in the same time period. Patients that underwent ablation beyond PVI (except for cavo-tricuspid isthmus ablation) were excluded. CB PVI was performed using the second-generation CB (CB 28 mm) with 240 sec based freeze protocol and bonus freeze delivery in case of time-to-isolation (TTI) >75 sec. PFA was performed using the Farawave catheter, using the 31 or 35 mm device. All procedures were performed under deep sedation. RESULTS: Data from 400 consecutive patients were collected. Most baseline characteristics like age (CB: 67,5 ± 15,3; PFA: 68,4 ± 11; p=0,49), BMI (CB: 28,6 ± 6,3; PFA: 27,9 ± 5,6; p=0,27) and gender (male) (CB: 54%; PFA: 59%; p=0,31) were comparable between the two groups. All PVIs were successfully completed. In 98% (196) of patients in the CB group and 100% (200) in the PFA group, PVI was performed using solely CB or PFA respectively, meaning additional touch up ablation was only needed in 4 CB patients (2%; p=0,044) and 4 veins. Procedure time was significantly shorter in the PFA group (CB: 53 ± 15,3 minutes; PFA: 36,8 ± 13,5 minutes; p<0,001), whereas no difference in fluoroscopy time (CB: 8,1 ± 4,4 minutes; PFA: 7,8 ± 3,3 minutes; p=0,2) was observed. The rate of concomitant CTI-ablation was equal in both groups (CB: 1,5%; PFA: 1,5%; p=1,0). Complication rate was 3,5% with PFA and 6,5% in CB (p=0,17), a difference mostly driven by persistent phrenic nerve palsies (CB: 1,5%; PFA: 0%; p=0,08). All patients are out of the blanking period. There were 80 recurrences in blanking time (CB: 41; PFA: 39; p=0,8). In CB 19,5% of blanking time recurrences were atrial tachycardias compared to 35,9% in PFA (p=0,1). The average time to blanking recurrence was 14,1 ± 21,5 days in CB and 20,5 ± 23,2 in PFA (p=0,2). In total, there were 7 repeat procedures (4 in CB and 3 in PFA; p=0,7) during blanking time due to arrhythmias, despite of antiarrhythmic drugs and/or cardioversion. At the time of this analysis, the first hundred patients in each group reached one-year follow-up. Recurrence free survival after one year for patients with PAF was 82,6% in CB and 80,0% in PFA. In patients with persistent AF it was 70,8% in CB and 67,8% in PFA. CONCLUSION: Cryoballoon and pulsed field ablation are both highly effective and safe techniques for PVI. PFA had a shorter procedure time, whereas the one year follow up was similar for both techniques. [Figure: see text] [Figure: see text] Oxford University Press 2023-05-24 /pmc/articles/PMC10207474/ http://dx.doi.org/10.1093/europace/euad122.691 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle 9.4.4 - Catheter Ablation of Arrhythmias
Urbanek, L
Bordignon, S
Schaack, D
Chen, S
Plank, K
Hirokami, J
Schulte-Hahn, B
Schmidt, B
Chun, K R J
Pulsed field versus cryoballoon ablation of atrial fibrillation: A comparison of efficacy and safety in a 400 patient cohort
title Pulsed field versus cryoballoon ablation of atrial fibrillation: A comparison of efficacy and safety in a 400 patient cohort
title_full Pulsed field versus cryoballoon ablation of atrial fibrillation: A comparison of efficacy and safety in a 400 patient cohort
title_fullStr Pulsed field versus cryoballoon ablation of atrial fibrillation: A comparison of efficacy and safety in a 400 patient cohort
title_full_unstemmed Pulsed field versus cryoballoon ablation of atrial fibrillation: A comparison of efficacy and safety in a 400 patient cohort
title_short Pulsed field versus cryoballoon ablation of atrial fibrillation: A comparison of efficacy and safety in a 400 patient cohort
title_sort pulsed field versus cryoballoon ablation of atrial fibrillation: a comparison of efficacy and safety in a 400 patient cohort
topic 9.4.4 - Catheter Ablation of Arrhythmias
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207474/
http://dx.doi.org/10.1093/europace/euad122.691
work_keys_str_mv AT urbanekl pulsedfieldversuscryoballoonablationofatrialfibrillationacomparisonofefficacyandsafetyina400patientcohort
AT bordignons pulsedfieldversuscryoballoonablationofatrialfibrillationacomparisonofefficacyandsafetyina400patientcohort
AT schaackd pulsedfieldversuscryoballoonablationofatrialfibrillationacomparisonofefficacyandsafetyina400patientcohort
AT chens pulsedfieldversuscryoballoonablationofatrialfibrillationacomparisonofefficacyandsafetyina400patientcohort
AT plankk pulsedfieldversuscryoballoonablationofatrialfibrillationacomparisonofefficacyandsafetyina400patientcohort
AT hirokamij pulsedfieldversuscryoballoonablationofatrialfibrillationacomparisonofefficacyandsafetyina400patientcohort
AT schultehahnb pulsedfieldversuscryoballoonablationofatrialfibrillationacomparisonofefficacyandsafetyina400patientcohort
AT schmidtb pulsedfieldversuscryoballoonablationofatrialfibrillationacomparisonofefficacyandsafetyina400patientcohort
AT chunkrj pulsedfieldversuscryoballoonablationofatrialfibrillationacomparisonofefficacyandsafetyina400patientcohort